Economic value of atopic dermatitis prevention via partially-hydrolyzed whey-based infant formula (PHF-W) use in high-risk, non-exclusively breastfed, Indonesian urban infants: results of a cost-effectiveness model

Marc F Botteman, Zakiudin Munasir, Astrid W Sulistomo, Erica G Horodniceanu, Abhijeet J Bhanegaonkar, Xiang Ji, Wing Yu Tang, Ray Wagiu Basrowi, Patrick Detzel

Abstract


Background:  Early nutritional intervention with partially-hydrolyzed whey-based formula (PHF-W) instead of standard cow’s milk formula (CMF) has been found to reduce the risk of atopic dermatitis (AD) development in non-exclusively breastfed infants with familial heredity of AD.

Objective:  To estimate the 6-year economic impact of this nutritional intervention in non-exclusively breastfed Indonesian urban infants with family history of AD.

Methods:  A mathematical model simulated AD incidence and burden of using PHF-W vs. CMF in the target population from birth to age 6. The model integrated literature, current cost and market catalogues, and expert clinician opinion. Modeled outcomes included AD risk, time spent post-AD diagnosis, days without flare, quality-adjusted life-years, and costs.

Results: Using PHF-W instead of CMF resulted in an estimated absolute 14% (95% CI: 4%, 23%) AD risk reduction, a 0.69 year (95% CI: 0.26, 1.13) per-child reduction in time spent post-AD diagnosis, a 38 (95% CI: 12, 67) increase in days without AD flare, and a 0.046 gain in quality-adjusted life-years. The AD-related 6-year cost estimates when feeding high-risk urban infants with PHF-W were Indonesian Rupiah (IDR) 8,695,057 (95% CI: IDR 4,519,447, IDR13,995,605) and IDR13,139,569 (95% CI: IDR 7,098,794, IDR 19,216,068) per child, respectively, resulting in a net per-child difference of IDR 4,444,512 (95% CI: IDR1,893,080, IDR 8,557,946) favoring PHF-W.

Conclusion: PHF-W for the first 17 weeks of non-exclusively breastfed Indonesian urban infants with a hereditary risk of AD demonstrated a reduction in AD incidence, increased days without flare, and increased quality-adjusted life-years and net cost reductions.


Keywords


cost effectiveness; atopic dermatitis; infant formula; hydrolyzed formula; Indonesia

Full Text:

PDF

References


--

Spergel JM, Paller AS. Atopic dermatitis and the atopic march. The Journal of allergy and clinical immunology 2003;112. [Google Scholar]

Catherine Mack Correa M, , Nebus J. . Management of patients with atopic dermatitis: the role of emollient therapy. Dermatology research and practice 2012; 2012. [Google Scholar]

Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. International journal of clinical practice 2006;60:984-92. [Google Scholar]

Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006;368:733-43. [Google Scholar]

Aziah MS, Rosnah T, Mardziah A, Norzila MZ. Childhood atopic dermatitis: a measurement of quality of life and family impact. The Medical journal of Malaysia 2002;57:329-39. [Google Scholar]

Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: its impact on the family and financial cost. Archives of disease in childhood 1997;76:159-62. [Google Scholar]

Williams H, Stewart A, Mutius, E. von , Cookson W, Anderson HR. International Study of Asthma and Allergies in Childhood (ISAAC) Phase One and Three Study Groups. Is eczema really on the increase worldwide. The Journal of allergy and clinical immunology 2008;121:947-54. [Google Scholar]

Anggraeni M, Wati KDK, Tangking K. Using family atopy scores to identify the risk of atopic dermatitis in infants. Paediatr Indones 2014;54:331. [Google Scholar]

Ngamphaiboon J, Kongnakorn T, Detzel P, Sirisomboonwong K, Wasiak R. Direct medical costs associated with atopic diseases among young children in Thailand. Journal of medical economics 2012;15:1025-35. [Google Scholar]

Kang KH, Kim KW, Kim DH. Utilization Pattern and Cost of Medical Treatment and Complementary Alternative Therapy in Children with Atopic Dermatitis. Pediatric Allergy and Respiratory Disease 2012;22:27-36. [Google Scholar]

Halken S, Host A, Hansen LG, Osterballe O. Effect of an allergy prevention programme on incidence of atopic symptoms in infancy. A prospective study of 159 "high-risk" infants. Allergy 1992;47:545-53. [Google Scholar]

Host A, Halken S, Muraro A, Dreborg S, Niggemann B, Aalberse R, et al. Dietary prevention of allergic diseases in infants and small children. Pediatr Allergy Immunol 2008;19:1-4. [Google Scholar]

World Health Organization. Infant and young child nutrition. Global strategy on infant and young child feeding. Report by the Secretariat. Fifty-fifth World Health Assembly2002 April 16. Report No.: A55/15. Provisional agenda item 13.10.

Berg, A. von , Filipiak-Pittroff B, Kramer U, Link E, Bollrath C, Brockow I, et al. Preventive effect of hydrolyzed infant formulas persists until age 6 years: long-term results from the German Infant Nutritional Intervention Study (GINI. The Journal of allergy and clinical immunology 2008;121:1442-7. [Google Scholar]

Berg, A. von , Filipiak-Pittroff B, Kramer U, Hoffmann B, Link E, Beckmann C, et al. Allergies in high-risk schoolchildren after early intervention with cow's milk protein hydrolysates: 10-year results from the German Infant Nutritional Intervention (GINI) study. The Journal of allergy and clinical immunology 2013;131:1565-73. [Google Scholar]

Greer FR, Sicherer SH, Burks AW, Immunology, o.N.a.S.o.A.a. (Committee) . Effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas. Pediatrics 2008;121:183-91. [Google Scholar]

Hays T, Wood RA. A systematic review of the role of hydrolyzed infant formulas in allergy prevention. Archives of pediatrics & adolescent medicine 2005;159:810-6. [Google Scholar]

Jin YY, Cao RM, Chen J, Kaku Y, Wu J, Cheng Y, et al. Partially hydrolyzed cow's milk formula has a therapeutic effect on the infants with mild to moderate atopic dermatitis: a randomized, double-blind study. Pediatr Allergy Immunol 2011;22:688-94. [Google Scholar]

Berg, A. von , Koletzko S, Grubl A, Filipiak-Pittroff B, Wichmann HE, Bauer CP, et al. The effect of hydrolyzed cow's milk formula for allergy prevention in the first year of life: the German Infant Nutritional Intervention Study, a randomized double-blind trial. The Journal of allergy and clinical immunology 2003;111:533-40. [Google Scholar]

Alexander DD, Cabana MD. Partially hydrolyzed 100% whey protein infant formula and reduced risk of atopic dermatitis: a meta-analysis. Journal of pediatric gastroenterology and nutrition 2010;50:422-30. [Google Scholar]

Host A, Koletzko B, Dreborg S, Muraro A, Wahn U, Aggett P, et al. Dietary products used in infants for treatment and prevention of food allergy. Joint Statement of the European Society for Paediatric Allergology and Clinical Immunology (ESPACI) Committee on Hypoallergenic Formulas and the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Committee on Nutrition. Archives of disease in childhood 1999;81:80-4. [Google Scholar]

Boyce JA, Assa'ad A, Burks AW, Jones SM, Sampson HA, Wood RA, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. The Journal of allergy and clinical immunology 2010;126. [Google Scholar]

Fleischer DM, Spergel JM, Assa'ad AH, Pongracic JA. Primary prevention of allergic disease through nutritional interventions. J Allergy Clin Immunol: In Practice 2013;1:29-36. [Google Scholar]

Iskedjian M, Belli D, Farah B, Navarro V, Detzel P. Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Swiss children. Journal of medical economics 2012;15:378-93. [Google Scholar]

Iskedjian M, Dupont C, Spieldenner J, Kanny G, Raynaud F, Farah B, et al. Economic evaluation of a 100% whey-based, partially hydrolysed formula in the prevention of atopic dermatitis among French children. Current medical research and opinion 2010;26:2607-26. [Google Scholar]

Iskedjian M, Haschke F, Farah B, Odijk, J. van , Berbari J, Spieldenner J. Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Danish children. Journal of medical economics 2012;15:394-408. [Google Scholar]

Iskedjian M, Szajewska H, Spieldenner J, Farah B, Berbari J. Meta-analysis of a partially hydrolysed 100%-whey infant formula vs. extensively hydrolysed infant formulas in the prevention of atopic dermatitis. Current medical research and opinion 2010;26:2599-606. [Google Scholar]

Su J, Prescott S, Sinn J, Tang M, Smith P, Heine RG, et al. Cost-effectiveness of partially-hydrolyzed formula for prevention of atopic dermatitis in Australia. Journal of medical economics 2012;15:1064-77. [Google Scholar]

Mertens J, Stock S, Lungen M, Berg, A. von , Kramer U, Filipiak-Pittroff B, et al. Is prevention of atopic eczema with hydrolyzed formulas cost-effective? A health economic evaluation from Germany. Pediatr Allergy Immunol 2012;23:597-604. [Google Scholar]

Spieldenner J, Belli D, Dupont C, Haschke F, Iskedjian M, Nevot Falco S , et al. Partially hydrolysed 100% whey-based infant formula and the prevention of atopic dermatitis: comparative pharmacoeconomic analyses. Annals of nutrition & metabolism 2011;59 Suppl 1:44-52. [Google Scholar]

Bhanegaonkar AJ, Horodniceanu EG, Gonzalez RRH, Mv CD, Detzel P, Erdogan-Ciftci E, et al. Cost-Effectiveness of Partially Hydrolyzed Whey Protein Formula in the Primary Prevention of Atopic Dermatitis in At-Risk Urban Filipino Infants. Value in Health Regional Issues 2014;3:124-35. [Google Scholar]

Beck JR, Pauker SG. The Markov process in medical prognosis. Medical decision making : An international journal of the Society for Medical Decision Making 1983;3:419-58. [Google Scholar]

Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Medical decision making : An international journal of the Society for Medical Decision Making 1993;13:322-38. [Google Scholar]

He ECE, Botteman MF, Detzel P, Verheggen BG. Cost-effectiveness analysis of 100% whey-based partially hydrolyzed infant formula used for prevention of atopic dermatitis in Germany [abstr. Value in Health 2012;15(7). [Google Scholar]

Pitt M, Garside R, Stein K. A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema. The British journal of dermatology 2006;154:1137-46. [Google Scholar]

Stevens KJ, Brazier JE, McKenna SP, Doward LC, Cork MJ. The development of a preference-based measure of health in children with atopic dermatitis. The British journal of dermatology 2005;153:372-7. [Google Scholar]

Chan YC, Tay YK, Sugito TL, Boediardja SA, Chau DD, Nguyen KV, et al. A study on the knowledge, attitudes and practices of Southeast Asian dermatologists in the management of atopic dermatitis. Annals of the Academy of Medicine, Singapore 2006;35:794-803. [Google Scholar]

Szajewska H, Horvath A. Meta-analysis of the evidence for a partially hydrolyzed 100% whey formula for the prevention of allergic diseases. Current medical research and opinion 2010;26:423-37. [Google Scholar]

Chan YH, Shek LP, Aw M, Quak SH, Lee BW. Use of hypoallergenic formula in the prevention of atopic disease among Asian children. Journal of paediatrics and child health 2002;38:84-8. [Google Scholar]

Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. The Journal of allergy and clinical immunology 2009;124:1251-8. [Google Scholar]

Bhanegaonkar AJ, Horodniceanu EG, Ah AL, Woodhull S, Khoo PC, Detzel P, et al. Economic value of atopic dermatitis prevention via infant formula use in high-risk Malaysian infants. Asia Pac Allergy 2015;5:84-97. [Google Scholar]

Tang M, Leong K, Ou LS, Munasir Z, Parekh PR, Azmi S, et al. Cost-Effectiveness Study of Pediatric Atopic Dermatitis in Asia: Atopiclair vs. Regular Emollient (AD-ATOP. Journal of drugs in dermatology: JDD 2015;14:169-75. [Google Scholar]

Botteman MF, Bhanegaonkar AJ, Horodniceanu EG, Ji X, Lee BW, Shek LP, et al. Economic value of using partially hydrolysed infant formula for risk reduction of atopic dermatitis in high-risk, not exclusively breastfed infants in Singapore. Singapore medical journal 2018;59(8):439. [Google Scholar]

--




DOI: https://doi.org/10.25220/WNJ.V02.i2.0008

Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Ray Wagiu Basrowi

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.